The FDA Group
The FDA Group is a privately held life science consulting and staffing firm, founded in 2007, that supplies former-FDA and industry subject matter experts to pharmaceutical, biologic, and medical device manufacturers for QA, regulatory affairs, audits, remediation, and AI-enabled compliance work.
- Company typePrivate
- Founded2007
- HeadquartersWestborough, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What The FDA Group does
The FDA Group is a privately held, Massachusetts-based life science consulting and staffing firm founded in 2007 that serves FDA-regulated industries including pharmaceutical, biologic, and medical device manufacturers. The company operates two complementary engagement models: project-based consulting engagements and contracted full-time staff augmentation, supplying subject matter experts across quality assurance, regulatory affairs, clinical operations, validation, and remediation functions. Its service catalog spans GxP audits and mock FDA inspections, regulatory submissions (IND, 510(k), ANDA, 505(b)(2)), Form 483 and warning letter remediation, quality management system development, and specialized support for QMSR transition, data integrity, and EU MDR/IVDR compliance.
The firm's core operational asset is a proprietary network of 3,750+ consultants spanning 75+ countries, including 325+ former FDA personnel, paired with a documented matching process that claims 95% first-time right-resource placement and 97% client satisfaction. In March 2026, the company commercially launched AICA (Audit Intelligence Compliance Assistant), a patent-pending, AI-powered compliance auditing platform that analyzes 100% of QMS documentation against 21 CFR Parts 11, 211, and 600. AICA is built on EPAM Systems' DIAL Open-Source GenAI Enterprise Platform and hosted on Microsoft Azure in the United States, with training supervision provided by 15+ in-house regulatory professionals.
Revenue is generated primarily through project-based and contracted consulting engagements sold via enterprise field sales to top-tier life science organizations, complemented by a subscription Insider Newsletter ($9.99-$29.99/month) and content/media assets (The Life Science Rundown podcast). Customer logos include Johnson & Johnson, Pfizer, Merck, Eli Lilly, Novo Nordisk, Sanofi, Bayer, Abbott, Medtronic, Stryker, Philips, Thermo Fisher Scientific, Regeneron, Takeda, and Fujifilm, with the company claiming penetration of 17 of the top 25 largest life science companies and 17 of the top 20 life science firms for remediation and consulting services respectively.
The FDA Group firmographics
Firmographics- Name
- The FDA Group
- Legal name
- The FDA Group, LLC
- Website
- https://thefdagroup.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- The FDA Group is a privately held life science consulting and staffing firm, founded in 2007, that supplies former-FDA and industry subject matter experts to pharmaceutical, biologic, and medical device manufacturers for QA, regulatory affairs, audits, remediation, and AI-enabled compliance work.
- Ownership category
- akta.pro rank
Where The FDA Group is headquartered
LocationHeadquarters
- HQ city
- Westborough
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
The FDA Group business model
Business model- GTM type
- B2B
- Offering type
- Services
Revenue model
- Staff Augmentation & Consulting: Providing contracted subject matter experts including former FDA and industry professionals for quality assurance, regulatory affairs, and clinical operations. Revenue generated through hourly/daily rates for contracted consultants placed with clients for project-based or ongoing engagements.
- Compliance Auditing Services: AICA platform for AI-powered QMS documentation auditing. Services include GMP, GLP, GCP audits, mock FDA inspections, gap assessments, and specialized compliance reviews.
- Regulatory Submissions: Support for drug and medical device regulatory submissions including IND applications, 510(k) filings, 505(b)(2) and ANDA submissions, FDA meeting preparation.
- Remediation Services: Quality system remediation, Form 483 response, warning letter response, data integrity remediation, and facility compliance remediation services.
- Insider Newsletter Subscription: Premium monthly newsletter delivering regulatory and compliance analysis from former FDA staff. Includes video content, transcripts, and exclusive resources. Billed at $29.99/month or promotional rates.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Insider Newsletter - Monthly Subscription |
| Subscription | Annual | Insider Newsletter - Annual Subscription with 50% discount |
| Other | Multi-year contract | Consulting & Staff Augmentation Services |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
The FDA Group product offering
Product offeringCore offering
No source-backed description is available. The input contained a planning note without attributable source IDs, so the core offering cannot be extracted.
Product overview
The FDA Group offers a portfolio of consulting services and technology products for FDA-regulated life science industries. The core product is AICA (Audit Intelligence Compliance Assistant), an AI-powered compliance auditing platform launched in March 2026, complemented by staff augmentation, regulatory submissions, audits/mock inspections, remediation services, and QMS consulting. The company also offers subscription content products including the Insider Newsletter and The Life Science Rundown podcast. The service model is primarily consulting-based (contracted subject matter experts), with AICA representing the company's first AI-powered software product.
Differentiator
Problem solved
Functional benefit
Brands
- AICA: Audit Intelligence Compliance Assistant - An AI-powered compliance auditing platform for pharmaceutical and biologic companies. Trained by 15+ regulatory professionals on real QMS documentation, it analyzes policies and procedures against FDA regulations to identify gaps in minutes or hours instead of days or weeks.
Quantifiable outcome
- 95% success rate in placing right resource first time
- +3 more outcomes
Companies that use The FDA Group
Customer profileNamed customers16 records
Segments5 records
Ideal customer profiles1 record
The FDA Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
The FDA Group partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- EPAM Systems, Inc.coreStrategic technology partnership for development of AICA (Audit Intelligence Compliance Assistant). EPAM contributed its DIAL Open-Source GenAI Enterprise Platform to build the AI-powered compliance auditing tool. The platform analyzes QMS documentation against FDA regulations, developed with expertise from 15+ regulatory professionals.
- Microsoft AzurecoreCloud infrastructure partner hosting AICA platform in the United States. Microsoft Azure provides the cloud environment for the AI-powered compliance auditing tool.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
The FDA Group competitors and assessment
Company assessmentBroad incumbents
- ICON plc: ICON plc is a global CRO providing clinical, regulatory, and laboratory services with deep pharma/biotech relationships. Broad incumbent competing for similar regulatory and quality consulting engagements at large life science clients.
- Parexel International: Parexel is a global CRO and biopharmaceutical services firm offering clinical, regulatory, and consulting services. Broad incumbent with overlapping regulatory affairs and compliance consulting capabilities serving the same pharma/biotech client base.
- IQVIA: IQVIA is the world's largest life sciences services provider spanning clinical research, real-world evidence, and regulatory/quality consulting. Broad incumbent that competes with The FDA Group for enterprise pharma and device consulting and staffing engagements.
Direct peers
- Validant: Validant is a regulatory and compliance consulting firm exclusively focused on the pharmaceutical, biotechnology, and medical device industries. Direct peer offering RA/QA consulting, remediation, and quality system services to FDA-regulated clients.
- ProPharma Group: ProPharma Group is a life sciences consulting and regulatory affairs services firm providing compliance, regulatory, and quality assurance support to pharma/biologic manufacturers. Highly comparable direct peer in FDA-regulated consulting and RA/QA staffing.
- Greenleaf Health: Greenleaf Health is an FDA regulatory consulting firm staffed by former senior FDA officials. Direct peer leveraging ex-FDA talent to advise pharma, biologic, and device companies on regulatory strategy and compliance.
- Lachman Consultant Services: Lachman Consultant Services provides regulatory affairs, compliance, and quality assurance consulting to the pharmaceutical and life sciences industries. Direct peer offering GMP, GLP, validation, and remediation services to FDA-regulated manufacturers.
Regional players
- MakroCare: MakroCare is a global clinical research and regulatory consulting firm with strong presence in India, Europe, and Asia. Comparable peer providing regulatory and clinical services to pharma and biotech, with significant overlap in regulatory affairs and quality consulting offerings.
Emerging players
- Veeva Systems: Veeva Systems provides cloud-based life sciences software including quality, regulatory, and compliance solutions. Closest software competitor to The FDA Group's AICA platform, offering regulated QMS and document/compliance tooling to overlapping pharma/biologic customers.
- MasterControl: MasterControl provides quality management software (eQMS) for life sciences and regulated manufacturers. Software comparator to AICA's AI compliance auditing, with overlapping GxP-focused customer base in pharma and medical device.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
The FDA Group social profiles
Digital presenceThe FDA Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
The FDA Group leadership team
Management profileNumber of profiles
The FDA Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The FDA Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The FDA Group
What does The FDA Group do?
No source-backed description is available. The input contained a planning note without attributable source IDs, so the core offering cannot be extracted.
Is The FDA Group a public or private company?
The FDA Group is a private company. It is classified as unknown and is currently operating.
When was The FDA Group founded?
The FDA Group was founded in 2007. It employs 11 to 50 people.
Where is The FDA Group based?
The FDA Group is headquartered in Westborough, United States, in the North America region.
How does The FDA Group make money?
Five revenue lines are on record. Staff Augmentation & Consulting is the primary driver. The others are compliance Auditing Services, regulatory Submissions, remediation Services and insider Newsletter Subscription.
Who are The FDA Group's main competitors?
Broad incumbents on record are ICON plc, Parexel International and IQVIA. Direct peers are Validant, ProPharma Group, Greenleaf Health and Lachman Consultant Services. MakroCare is listed as a regional player. Emerging players are Veeva Systems and MasterControl.
Does The FDA Group have an API?
No public API is recorded for The FDA Group.